Medizinische Klinik III (Kardiologie, Angiologie/Hämostase, Funktionsbereich Nephrologie)
1.4. Wissenschaftliche Veröffentlichungen Journalbeitrag
3. Haberl A (2013) HIV und Frauen. In: Hoffmann C, Rockstroh J (Hg.) MEDIZIN FOKUS VERLAG, Hamburg, 500-503
Habilitation
1. Brandts C (2013) Konstitutive onkogene Aktivierung der PI3-Kinase- und STAT-Signaltransduktionswege in der malignen Transformation. Habilitation Universität Universität Frankfurt
Dissertation
1. Bossert B (2013) Vergleich von Effektivität und Nebenwirkungen von drei Erstlinien-Therapieregimen bei Patienten ab 59 Jahren aus der Frankfurter HIV-Kohorte. Dissertation Universität Frankfurt
2. Dubey A (2013) Der Einfluss des DEK/CAN-Fusionsproteins auf die Apoptose bei der t(6;9) positiven Akuten Myeloischen Leukämie. Dissertation Universität Frankfurt
3. Fuß BM (2013) Umstellung der antiretroviralen Therapie nach HIV-Resistenztestung:
Behandlungsverläufe und Risikofaktoren für virologisches Versagen in der Frankfurter HIV-Kohorte. Dissertation Universität Frankfurt
4. Heß S (2013) Graft-versus-Host Disease und Virus-DNA im Gastrointestinaltrakt: Eine retrospektive Kohortenanalyse von allogen transplantierten Patienten am Universitätsklinikum Frankfurt am Main. Dissertation Universität Frankfurt
5. Jesche RP (2013) Fieber bei Reiserückkehrern - Korrelation von Aufnahme- und Abschlussdiagnosen. Dissertation Universität Frankfurt
Medizinische Klinik III (Kardiologie, Angiologie/Hämostase,
patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. INT J CARDIOL, 170 (2): 215-20
4. Beiras-Fernandez A, Weis F, Rothkopf J, Kaczmarek I, Ledderose C, Dick A, Keller T, Beiras A, Kreth S (2013) Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. ANN TRANSPL, 18: 643-50
5. Biener M, Mueller M, Vafaie M, Keller T, Blankenberg S, White HD, Katus HA, Giannitsis E (2013) Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. INT J CARDIOL, 167 (4): 1134-40
6. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Tréguer K, Carmona G, Bonauer A, Horrevoets AJG, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, Müller OJ, Potente M, Zeiher AM, Hermeking H, Dimmeler S (2013) MicroRNA-34a regulates cardiac ageing and function. NATURE, 495 (7439): 107-10
7. Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, Zeiher AM, Gaetano C (2013) Oxidative stress and epigenetic regulation in ageing and age-related diseases. INT J MOL SCI, 14 (9):
17643-63
8. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD (2013) Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). EUR HEART J, 34 (20): 1498-505
9. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S (2013) The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
CIRCULATION, 128 (3): 237-43
10. De Rosa S, Seeger FH, Honold J, Fischer-Rasokat U, Lehmann R, Fichtlscherer S, Schächinger V, Dimmeler S, Zeiher AM, Assmus B (2013) Procedural safety and predictors of acute outcome of intracoronary administration of progenitor cells in 775 consecutive procedures performed for acute myocardial infarction or chronic heart failure. CIRC-CARDIOVASC INTE, 6 (1): 44-51 11. Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G,
Agostini C, Cappellari R, Boscaro E, Zeiher A, Dimmeler S, Avogaro A (2013) Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. BASIC RES CARDIOL, 108 (1): 313
12. Fadini GP, de Kreutzenberg SV, Boscaro E, Albiero M, Cappellari R, Kränkel N, Landmesser U, Toniolo A, Bolego C, Cignarella A, Seeger F, Dimmeler S, Zeiher A, Agostini C, Avogaro A (2013) An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. DIABETOLOGIA, 56 (8): 1856-66 13. Fox H, Büttner S, Hemmann K, Asbe-Vollkopf A, Doss M, Beiras-Fernandez A, Moritz A,
Zeiher AM, Scheuermann E, Geiger H, Fichtlscherer S, Hauser IA, Lehmann R (2013) Transcatheter aortic valve implantation improves outcome compared to open-heart surgery in kidney transplant recipients requiring aortic valve replacement. J CARDIOL, 61 (6): 423-7 14. Fox H, Hemmann K, Doss M, Beiras-Fernandez A, Zeiher AM, Moritz A, Fichtlscherer S,
Lehmann R (2013) Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia. BLOOD COAGUL FIBRIN, 24 (7): 732-5
15. Hemmann K, Sirotina M, De Rosa S, Ehrlich JR, Fox H, Weber J, Moritz A, Zeiher AM, Hofmann I, Schächinger V, Doss M, Sievert H, Fichtlscherer S, Lehmann R (2013) The STS score is the strongest predictor of long-term survival following transcatheter aortic valve implantation, whereas access route (transapical versus transfemoral) has no predictive value beyond the periprocedural phase. INTERACT CARDIOV TH, 17 (2): 359-64
16. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJV, Granger CB (2013) N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial
fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J AM COLL CARDIOL, 61 (22): 2274-84
17. Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu QF, Baloch E, van Rooij E, Zeiher AM, Kupatt C, Dimmeler S (2013) Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. CIRCULATION, 128 (10): 1066-75
18. Hohnloser SH, Camm AJ (2013) Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. EUROPACE, 15 (10): 1407-11 19. Hohnloser SH, Shestakovska O, Eikelboom J, Franzosi MG, Tan RS, Zhu J, Yusuf S, Connolly
SJ (2013) The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. EUR HEART J, 34 (35): 2752-9
20. Honold J, DeRosa S, Spyridopoulos I, Fischer-Rasokat U, Seeger FH, Leistner D, Lotz S, Levy WC, Zeiher AM, Assmus B (2013) Comparison of the Seattle heart failure model and cardiopulmonary exercise capacity for prediction of death in patients with chronic ischemic heart failure and intracoronary progenitor cell application. CLIN CARDIOL, 36 (3): 153-9
21. Honold J, Fischer-Rasokat U, Seeger FH, Leistner D, Lotz S, Dimmeler S, Zeiher AM, Assmus B (2013) Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure. CLIN RES CARDIOL, 102 (9): 619-25
22. Honold J, Thieme F, Zeuzem S, Serve H, Fichtlscherer S, Zeiher AM, Walcher F, Marzi I, Lehmann R (2013) [Characterization and economic impact of medical patients presenting at the emergency department of an university hospital]. DEUT MED WOCHENSCHR, 138 (27): 1401-5
23. Kaluza D, Kroll J, Gesierich S, Manavski Y, Boeckel JN, Doebele C, Zelent A, Rössig L, Zeiher AM, Augustin HG, Urbich C, Dimmeler S (2013) Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. ARTERIOSCL THROM VAS, 33 (3): 533-43
24. Keller T, Ojeda F, Zeller T, Wild PS, Tzikas S, Sinning CR, Peetz D, Münzel T, Blankenberg S, Lackner KJ (2013) Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay. INT J CARDIOL, 167 (4): 1423-9
25. Kettering K, Gramley F (2013) Catheter ablation of atrial fibrillation: Radiofrequency catheter ablation for redo procedures after cryoablation. WORLD J CARDIOL, 5 (8): 280-7
26. Koellensperger E, Niesen W, Kolbenschlag J, Gramley F, Germann G, Leimer U (2013) Human adipose tissue derived stem cells promote liver regeneration in a rat model of toxic injury. STEM CELLS INT, 2013: 534263
27. Lau CP, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, Israel CW, Morillo CA, Siu CW, Abe H, Carlson M, Tse HF, Hohnloser SH, Healey JS, ASSERT investigators (2013) Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J CARDIOVASC ELECTR, 24 (4): 381-7
28. Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. CLIN RES CARDIOL, 102 (4):
259-68
29. Martin M, Geudens I, Bruyr J, Potente M, Bleuart A, Lebrun M, Simonis N, Deroanne C, Twizere JC, Soubeyran P, Peixoto P, Mottet D, Janssens V, Hofmann WK, Claes F, Carmeliet P, Kettmann R, Gerhardt H, Dequiedt F (2013) PP2A regulatory subunit Bα controls endothelial contractility and vessel lumen integrity via regulation of HDAC7. EMBO J, 32 (18): 2491-503 30. Michaelis UR, Chavakis E, Kruse C, Jungblut B, Kaluza D, Wandzioch K, Manavski Y, Heide H,
Santoni MJ, Potente M, Eble JA, Borg JP, Brandes RP (2013) The polarity protein Scrib is essential for directed endothelial cell migration. CIRC RES, 112 (6): 924-34
31. Neumann JT, Tzikas S, Funke-Kaiser A, Wilde S, Appelbaum S, Keller T, Ojeda-Echevarria F, Zeller T, Zwiener I, Sinning CR, Jagodzinski A, Schnabel RB, Lackner KJ, Münzel T, Blankenberg S, Wild PS, Sydow K (2013) Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. ATHEROSCLEROSIS, 228 (2): 451-9
32. Nikolic I, Stankovic ND, Bicker F, Meister J, Braun H, Awwad K, Baumgart J, Simon K, Thal SC, Patra C, Harter PN, Plate KH, Engel FB, Dimmeler S, Eble JA, Mittelbronn M, Schäfer MK,
Jungblut B, Chavakis E, Fleming I, Schmidt MHH (2013) EGFL7 ligates αvβ3 integrin to enhance vessel formation. BLOOD, 121 (15): 3041-50
33. Ohtani K, Zhao C, Dobreva G, Manavski Y, Kluge B, Braun T, Rieger MA, Zeiher AM, Dimmeler S (2013) Jmjd3 controls mesodermal and cardiovascular differentiation of embryonic stem cells. CIRC RES, 113 (7): 856-62
34. Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, Chakrabarti A, Howard LS, Gibbs JSR, Lawrie A, Condliffe R, Elliot CA, Kiely DG, Huson L, Ghofrani HA, Tiede H, Schermuly R, Zeiher AM, Dimmeler S, Wilkins MR (2013) Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. AM J RESP CRIT CARE, 187 (3): 294-302
35. Schwietz T, Ehrlich JR, De Rosa S, Fichtlscherer S, Schächinger V, Baier G, Laskowski R, Zeiher AM, Spyridopoulos I, Lehmann R (2013) Prognostic impact of using drug-eluting-stents on outcome and strategy in multivessel PCI: data from the Frankfurt MV-PCI registry. J CARDIOL, 61 (1): 38-43
36. Schwietz T, Spyridopoulos I, Pfeiffer S, Laskowski R, Palm S, DE Rosa S, Jens K, Zeiher AM, Schächinger V, Fichtlscherer S, Lehmann R (2013) Risk stratification following complex PCI:
clinical versus anatomical risk stratification including "post PCI residual SYNTAX-score" as quantification of incomplete revascularization. J INTERV CARDIOL, 26 (1): 29-37
37. Seeger FH, Toenne M, Lehmann R, Ehrlich JR (2013) Simplistic approach to prognosis after cardiopulmonary resuscitation-value of pH and lactate. J CRIT CARE, 28 (3): 317.e13-20
38. Seeger T, Haffez F, Fischer A, Koehl U, Leistner DM, Seeger FH, Boon RA, Zeiher AM, Dimmeler S (2013) Immunosenescence-associated microRNAs in age and heart failure. EUR J HEART FAIL, 15 (4): 385-93
39. Seizer P, Geisler T, Bigalke B, Schneider M, Klingel K, Kandolf R, Stellos K, Schreieck J, Gawaz M, May AE (2013) EMMPRIN and its ligand cyclophilin A as novel diagnostic markers in inflammatory cardiomyopathy. INT J CARDIOL, 163 (3): 299-304
40. Sinning C, Lillpopp L, Appelbaum S, Ojeda F, Zeller T, Schnabel R, Lubos E, Jagodzinski A, Keller T, Munzel T, Bickel C, Blankenberg S (2013) Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. CLIN RES CARDIOL, 102 (7): 495-503
41. Stakos DA, Gatsiou A, Stamatelopoulos K, Tselepis AD, Stellos K (2013) Platelet microRNAs:
From platelet biology to possible disease biomarkers and therapeutic targets. Platelets, 24 (8):
579-89
42. Staubach S, Franke J, Gerckens U, Schuler G, Zahn R, Eggebrecht H, Hambrecht R, Sack S, Richardt G, Horack M, Senges J, Steinberg DH, Ledwoch J, Fichtlscherer S, Doss M, Wunderlich N, Sievert H, German Transcatheter Aortic Valve Implantation-Registry Investigators (2013) Impact of aortic valve calcification on the outcome of transcatheter aortic valve implantation:
results from the prospective multicenter German TAVI registry. CATHETER CARDIO INTE, 81 (2): 348-55
43. Stellos K, Bigalke B, Borst O, Pfaff F, Elskamp A, Sachsenmaier S, Zachmann R, Stamatelopoulos K, Schönberger T, Geisler T, Langer H, Gawaz M (2013) Circulating platelet-progenitor cell coaggregate formation is increased in patients with acute coronary syndromes and augments recruitment of CD34+ cells in the ischaemic microcirculation. EUR HEART J, 34 (32):
2548-56
44. Tzikas S, Keller T, Ojeda FM, Zeller T, Wild PS, Lubos E, Kunde J, Baldus S, Bickel C, Lackner KJ, Münzel TF, Blankenberg S (2013) MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. HEART, 99 (6): 388-95
45. Tzikas S, Keller T, Wild PS, Schulz A, Zwiener I, Zeller T, Schnabel RB, Sinning C, Lubos E, Kunde J, Münzel T, Lackner KJ, Blankenberg S (2013) Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study. CLIN CHEM LAB MED, 51 (5): 1125-33
46. von Haehling S, Doehner W, Jankowska EA, Ponikowski P, Stellos K, Puntmann VO, Nagel E, Anker SD, Gawaz M, Bigalke B (2013) Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. CAN MED ASSOC J, 185 (7): E295-303
47. von Haehling S, Stellos K, Qusar N, Gawaz M, Bigalke B (2013) Weight reduction in patients with coronary artery disease: comparison of Traditional Tibetan Medicine and Western diet. INT J CARDIOL, 168 (2): 1509-15
48. Wagner J, Riwanto M, Besler C, Knau A, Fichtlscherer S, Röxe T, Zeiher AM, Landmesser U, Dimmeler S (2013) Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. ARTERIOSCL THROM VAS, 33 (6): 1392-400
49. Wurster T, Poetz O, Stellos K, Kremmer E, Melms A, Schuster A, Nagel E, Joos T, Gawaz M, Bigalke B (2013) Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke. Platelets, 24 (7): 560-5
50. Wurster T, Stellos K, Haap M, Seizer P, Geisler T, Otton J, Indermuehle A, Ishida M, Schuster A, Nagel E, Gawaz M, Bigalke B (2013) Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS? INT J CARDIOL, 164 ((SDF-1): 111-5
51. Zehendner CM, Librizzi L, Hedrich J, Bauer NM, Angamo EA, de Curtis M, Luhmann HJ (2013) Moderate hypoxia followed by reoxygenation results in blood-brain barrier breakdown via oxidative stress-dependent tight-junction protein disruption. PLoS One, 8 (12): e82823
52. Zehendner CM, Luhmann HJ, Yang JW (2013) A simple and novel method to monitor breathing and heart rate in awake and urethane-anesthetized newborn rodents. PLoS One, 8 (5): e62628 53. Zehendner CM, Tsohataridis S, Luhmann HJ, Yang JW (2013) Developmental switch in
neurovascular coupling in the immature rodent barrel cortex. PLoS One, 8 (11): e80749
54. Zehendner CM, Wedler HE, Luhmann HJ (2013) A novel in vitro model to study pericytes in the neurovascular unit of the developing cortex. PLoS One, 8 (11): e81637
Review
1. Graupera M, Potente M (2013) Regulation of angiogenesis by PI3K signaling networks. EXP CELL RES, 319 (9): 1348-55
2. Hohnloser SH, Israel CW (2013) Current evidence base for use of the implantable cardioverter-defibrillator. CIRCULATION, 128 (2): 172-83
3. Merchant FM, Zheng H, Bigger T, Steinman R, Ikeda T, Pedretti RFE, Salerno-Uriarte JA, Klersy C, Chan PS, Bartone C, Hohnloser SH, Ruskin JN, Armoundas AA (2013) A combined anatomic and electrophysiologic substrate based approach for sudden cardiac death risk stratification. AM HEART J, 166 (4): 744-52
4. Seeger FH, Zeiher AM, Dimmeler S (2013) MicroRNAs in stem cell function and regenerative therapy of the heart. ARTERIOSCL THROM VAS, 33 (8): 1739-46
Letter
1. Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S (2013) Heparin selectively affects the quantification of microRNAs in human blood samples. CLIN CHEM, 59 (7): 1125-7
Fallbericht
1. Fox H, Seeger FH (2013) Tetanus in a patient with a maggot-colonised head tumor. ANAESTH INTENS CARE, 41 (2): 272-3
Kommentar oder Korrespondenz
1. Assmus B, Zeiher AM (2013) Early cardiac retention of administered stem cells determines clinical efficacy of cell therapy in patients with dilated cardiomyopathy. CIRC RES, 112 (1): 6-8 2. Hijazi Z, Oldgren J, Wallentin L, Andersson U, Connolly SJ, Yusuf S, Ezekowitz MD, Hohnloser
SH, Reilly PA, Vinereanu D, Siegbahn A (2013) Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy".
CIRCULATION, 127 (2): e278-9
3. Losordo DW, Zeiher AM (2013) Angels and Demons: part II. CIRC RES, 113 (1): 20-1 Habilitation
1. Keller T (2013) Biomarker in der Diagnose des Akuten Myokardinfarktes unter besonderer Berücksichtigung kardialer Troponine.
2. Stellos K (2013) Neue Aspekte von Thrombozytenfunktion bei Patienten mit Koronarer Herzerkrankung.
Dissertation
1. Baier GH (2013) Einfluss der Einführung von "drug-eluting" Stents auf die Prognose von Patienten nach koronarer Mehrgefäßintervention.
2. Weber V (2013) Die Etablierung des transradialen Verfahrens für koronare Interventionen und Vergleich mit dem transfemoralen Verfahren.
2. Schwerpunkt Angiologie/Hämostaseologie Leiterin: Prof. Dr. Edelgard Lindhoff-Last Wissenschaftliche Veröffentlichungen Journalbeitrag
Originalarbeit
1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. NEW ENGL J MED, 369 (9): 799-808
2. Kasper A, Lindhoff-Last E (2013) [Monitoring of coagulation during treatment with direct oral anticoagulants]. DEUT MED WOCHENSCHR, 138 (40): 1997-2000
3. Kraft C, Hecking C, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B (2013) Patients with inferior vena cava thrombosis frequently present with lower back pain and bilateral lower-extremity deep vein thrombosis. VASA, 42 (4): 275-83
4. Lindhoff-Last E, Ansell J, Spiro T, Samama MM (2013) Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. ANN MED, 45 (5-6): 423-9
5. Linnemann B, Lindhoff-Last E (2013) [Lower extremity deep vein thrombosis - diagnostic algorithm]. DEUT MED WOCHENSCHR, 138 (8): 369-74
6. Mani H, Hesse C, Stratmann G, Lindhoff-Last E (2013) Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost, 109 (1): 127-36
7. Mani H, Kasper A, Lindhoff-Last E (2013) Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J THROMB THROMBOLYS, 36 (2): 187-94
8. Mani H, Lindhoff-Last E (2013) Main considerable factors for correct laboratory test interpretation under DOA treatment. THROMB J, 11 (1): 22
9. Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C (2013) The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. CEREBROVASC DIS, 36 (2): 115-9
10. Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ (2013) High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J ALLERGY CLIN IMMUN, 132 (1): 131-9
11. Weingarz L, Schwonberg J, Schindewolf M, Hecking C, Wolf Z, Erbe M, Weber A, Lindhoff-Last E, Linnemann B (2013) Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. BRIT J HAEMATOL, 163 (5): 655-65
Supplement
1. Linnemann B, Lindhoff-Last E (2013) [Management of catheter-related upper extremity deep vein thrombosis]. Zentralbl Chir, 138 Suppl 2: e86-94
Kommentar oder Korrespondenz
1. Linnemann B (2013) [Vena cava filters in pulmonary embolism: temporary or permanent?--Cava filters have to be removed early]. DEUT MED WOCHENSCHR, 138 (24): 1294
3. Funktionsbereich Nephrologie Leiter: Prof. Dr. Helmut Geiger